ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0502

Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study

Gerd Burmester1, Jakub Trefler2, Artur Racewicz3, Janusz Jaworski4, Agnieszka Zielińska5, Marek Krogulec6, Sławomir Jeka7, Rafał Wojciechowski8, Katarzyna Kolossa9, Anna Dudek10, Magdalena Krajewska-Włodarczyk11, Paweł Hrycaj12, Piotr Adrian Klimiuk13, SungHyun Kim14, JeeHye Suh14, GoEun Yang14, Yunah Kim14, YooBin Jung14, JiWoo Hong14 and Josef Smolen15, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2REUMA RESEARCH, Wrocław, Poland, 3Zdrowie Osteo-Medic, Warszawa, Poland, 4Reumatika-Centrum Reumatologii, Warszawa, Poland, 5MICS Centrum Medyczne Warszawa, Warszawa, Poland, 6NZOZ Lecznica MAK - MED, Nadarzyn, Poland, 7MICS Centrum Medyczne, Polska, Poland, 8Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, 9MICS Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland, 10Centrum Medyczne Amed, Warszawa, Poland, 11University of Warmia and Mazury, Clinic of Rheumatology, Olsztyn, Poland, 12Prywatna Praktyka Lekarska Prof. dr hab. med. Paweł, Poznań, Poland, 13Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, 14Celltrion, Inc., Incheon, Republic of Korea, 15Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2024

Keywords: clinical trial, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The therapeutic equivalence of CT-P47 (a proposed biosimilar to reference tocilizumab [ref-tocilizumab]) was demonstrated in patients with moderate to severe RA through disease activity scores using 28 joints (DAS28) at Weeks 12 and 24 in line with different regulatory requirement. Comparable clinical efficacy and safety up to Week 32 have also been confirmed1. Here, we present the efficacy, pharmacokinetics (PK) and safety of CT-P47 over 1-year, including the outcomes of single transition from ref-tocilizumab to CT-P47.

Methods: 471 moderate-to-severe RA patients who had an inadequate response to ≥1 disease-modifying antirheumatic drugs were randomized (1:1) to receive 8 mg/kg of CT-P47 or ref-tocilizumab intravenously every 4 weeks up to Week 20. Prior to dosing at Week 24, 444 patients were randomized again to either maintain their treatments or switch from ref-tocilizumab to CT-P47, continuing treatment until week 48, followed by a 4-week follow-up period. Efficacy, PK, safety, and immunogenicity were evaluated throughout the study period.

Results: Of 444 patients re-randomized (225 in CT-P47 maintenance, 109 in ref-tocilizumab maintenance, and 110 in Switched to CT-P47), 412 (92.8%) patients completed the treatment and the study (210 in CT-P47 maintenance, 100 in ref-tocilizumab maintenance, and 102 in Switched to CT-P47). The mean change from baseline of DAS28 (ESR) was not affected by transition from ref-tocilizumab to CT-P47 at Week 24, and comparable improvement in clinical activity was observed up to Week 52 (end-of-study [EOS] visit). The rates of ACR20/50/70 and remissions by CDAI, SDAI, and Boolean-definition (v2.0) also showed similar responses among the groups after transition (Table 1). Mean pre-dose serum concentration was similar among the groups up to Week 52 (EOS) (Week 52: CT-P47 Maintenance; 16.73 μg/mL vs ref-tocilizumab Maintenance; 17.41 μg/mL vs Switched to CT-P47; 17.32 μg/mL). The safety profiles from Weeks 24 to 52 (EOS) after transition were generally comparable across the groups. Additionally, those patients who continued to receive CT-P47 or ref-tocilizumab for the entire 52-week period also showed comparable results (Table 2). The proportion of patients who had at least 1 anti-drug antibody positive result at post-treatment after re-randomization was similar among the groups (CT-P47 Maintenance: 4.4% vs. ref-tocilizumab Maintenance: 4.6% vs. Switched to CT-P47: 3.6%), and 1.8% of patients in each group also had at least 1 neutralizing antibody positive result.

Conclusion: The study showed that CT-P47 was well tolerated over 1 year in patients with RA, with comparable efficacy, PK, safety, and immunogenicity to those of ref-tocilizumab. In addition, the efficacy has been sustained after switching from ref-tocilizumab to CT-P47 and no notable safety issue was identified following single transition.

Reference: 1.  Smolen, et al. POS0610 Similar Efficacy, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 32 Results from the Phase III Single Transition Study. Ann Rheum Dis. 2024.

Supporting image 1

Supporting image 2


Disclosures: G. Burmester: AbbVie, 2, Amgen, 2, BMS, 2, Galapagos, 2, Lilly, 2, MSD, 2, Pfizer, 2, Sanofi, 2; J. Trefler: None; A. Racewicz: None; J. Jaworski: None; A. Zielińska: None; M. Krogulec: None; S. Jeka: AbbVie/Abbott, 6, Eli Lilly, 6, Gilead, 6, Janssen, 6, Merck/MSD, 6, Novartis, 6, UCB, 6; R. Wojciechowski: AbbVie/Abbott, 6, Eli Lilly, 6, Novartis, 5, 6, UCB, 6; K. Kolossa: None; A. Dudek: None; M. Krajewska-Włodarczyk: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 1, 6, Janssen, 6, Merck/MSD, 6, Novartis, 6, UCB, 1, 6; P. Hrycaj: None; P. Klimiuk: None; S. Kim: Celltrion, Inc., 3; J. Suh: Celltrion, Inc., 3; G. Yang: Celltrion, Inc., 3; Y. Kim: Celltrion, Inc., 3; Y. Jung: Celltrion, Inc., 3; J. Hong: Celltrion, Inc., 3; J. Smolen: Abbvie, 5, 6, Amgen, 6, Astra-Zeneca, 5, 6, Astro, 6, Bristol-Myers Squibb, 6, Celgene, 6, Celltrion, 6, Chugai, 6, Eli Lilly, 5, 6, Gilead, 6, ILTOO, 6, Janssen, 6, Merck Sharp & Dohme, 6, Novartis, 5, 6, Pfizer, 6, Roche, 5, 6, R-Pharma, 6, Samsung, 6, Sanofi, 6, UCB Pharma, 6.

To cite this abstract in AMA style:

Burmester G, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk P, Kim S, Suh J, Yang G, Kim Y, Jung Y, Hong J, Smolen J. Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/similar-efficacy-pk-safety-and-immunogenicity-of-tocilizumab-biosimilar-ct-p47-and-reference-tocilizumab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-week-52-results-from-the/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/similar-efficacy-pk-safety-and-immunogenicity-of-tocilizumab-biosimilar-ct-p47-and-reference-tocilizumab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-week-52-results-from-the/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology